Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 44Carcinoma, Hepatocellular 42Small Cell Lung Carcinoma 28Breast Neoplasms 18Cholangiocarcinoma 17Urinary Bladder Neoplasms 16Biliary Tract Neoplasms 15Liver Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 9Carcinoma 9Squamous Cell Carcinoma of Head and Neck 8Endometrial Neoplasms 7Colorectal Neoplasms 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Melanoma 5Gallbladder Neoplasms 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasms by Site 4Mesothelioma 4

Interventions

atezolizumab 2Carboplatin 2durvalumab 1anlotinib 1Radiotherapy 1Paclitaxel 1Immunotherapy 1Immune Checkpoint Inhibitors 1Etoposide 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Cancer Extensive Stage × durvalumab × 1 year × Clear all
NCT05856695 2025-09-24

TAXIO

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Active not recruiting
67 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡